- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Patrick Burnett Discusses Risk Factors for Adverse Behavioral Health, QOL in Psoriasis
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.
Severity, location, and symptom burden of psoriasis are 3 key factors associated with risk of adverse behavioral health and quality of life issues in patients, said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics.
Transcript
Can you discuss risk factors for adverse behavioral outcomes in patients with psoriasis?
I think the extent of the disease that a patient has is really important in that, as well as the location, and then their symptoms. So, if we think about those 3 factors, the extent of disease—obviously if a patient only has the typical plaque psoriasis locations and it's a very low percentage of their overall body surface area (BSA) or maybe it's in an area that is easily hidden from public viewing during their regular week, then the impact of that on their quality of life may be somewhat less. We certainly see a correlation between that and more severe disease, and severe disease usually means higher BSA. And so that's one aspect that I think is important.
The other one is the location. So, we talked about intertriginous psoriasis as a key location. Obviously, and even in our Harris Poll data, we found out that intertriginous disease has a big impact on those intimate aspects of a patient's life. So, sexual function, comfort with engaging in sexual activity—those are impacted by a patient having intertriginous psoriasis, because although it may not be visible to people in your daily life, in those moments, it becomes very important to you. And that's an important aspect of life and something that oftentimes patients might not be talking about.
And then the third aspect, I would say, is really the symptoms. So, if a patient is very symptomatic, and the number one symptom is itch in psoriasis, then that's going to have an impact on their quality of life and can kind of repeatedly disrupt their normal activities throughout the day because they're focusing more so on their psoriasis than on what they're meant to be paying attention to in their work or in caring for their family or whatever it is that they spend their day doing.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
